1Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review[ J]. Pulm Pharmacol Ther ,2011.
2Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD [ J ]. Treat Respir Med,2004,3 (4) :247.
3Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-actlng beta-agonists monotherapy for stable COPD:a systematic review[J]. Chest,2009,136(4): 1029.
4Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD[ J]. Respir Med,2011.
5Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J]. N Engl J Med ,2007,356( 8 ) : 775.
6Truosters T, Celli B, Lystig T, et al. UPLIFT Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFF trial [ J ]. Eur Resp J, 2010,36( 1 ) :65.
3Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China : a large, population-based survey[ J]. Am J Respir Crit Care Med, 2007,176 ( 8 ) :753-760.
4Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists [ J ]. J Allergy Clin Immunol , 2002,110 ( 6 Suppl) : S261-S268.
